

UnitedHealthcare Community Plan Pharmacy & Therapeutics Committee Minutes

Meeting Date: March 9, 2023
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/ Recommendations	Vote
Meeting called to order	G. Shutzberg	5:01 PM EST		
A. Minutes from previous meetings	G. Shutzberg	Review of Minutes from December 8, 2022	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs	M. Reisman	Auvelity		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Dr. Pappalardo asked about the minimum age for use of Auvelity & what do we know about its addictive potential. It's indicated in adults. Dextromethorphan has the potential for misuse but has little dependence liability. Dr. Williams asked what the cost of Auvelity versus the cost of the individual ingredients used in combination. Using the individual ingredients in combination would be significantly less expensive.		
	M. Reisman	Lytgobi		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	M. Reisman	Relyvrio		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Lichtinger	Rolvedon		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	C. Lichtinger	Xaciato		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Dr. Fitzhugh asked about use of Xaciato in recurrent BV. The trials did include patients with recurrent BV and found the success rate to be similar.		
	C. Lichtinger	Xelstrym		
		Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
C. Formulary Review - Class Review	M. Reisman	Targeted Immune Modulators and Related Agents		
		Recommendation: • Sotyktu : Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Amjevita : Preferred with prior authorization across all applicable lines of business on 3/1/2023 • Humira and adalimumab biosimilars : Upon full review and market availability of pending products, move Humira to a non-preferred position, adding up to 3 biosimilars as preferred alternatives requiring prior authorization, across all applicable lines of business. Transition current utilizers of Humira to one of the preferred biosimilars across all applicable lines of business.	Motion made, seconded, and carried to accept recommendation	10:0
D. Formulary Review - New Formulations	M. Reisman	Confirm Review of New Formulations Grid	Yes/No	Yes
		Recommendation: • Leuprolide acetate 22.5mg depot injection : Preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
E. Formulary Review - PDL Modifications	M. Reisman	Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Xerac- AC : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • moxifloxacin 400mg tablet : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Dr. Pappalardo asked, is there a disadvantage for making Moxifloxacin preferred, due to concerns about antibiotic resistance. We would expect that the prescribers monitor resistance patterns, the goal is to not be a barrier to care for an acute use drug.		
		Recommendation: • nadolol : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • zolpidem ER : Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
	Comment:	Dr. Tepper asked if we have an age edit on zolpidem? We do not, but we have other tools we can use to ensure appropriate use, such as DUR edits.		
		Recommendation: • Nutropin AQ : Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Zomacton : Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • linezolid tablets and suspension : Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • lurasidone : Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Adderall (amphetamine- dextroamphetamine) 20mg tablet : Increase the quantity limit to 3 tablets per day across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • Adderall (amphetamine- dextroamphetamine) XR capsule : Increase the quantity limit to 2 capsules per day across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Recommendation: • OneTouch Meters : Increase the quantity limit to 1 meter per 2 years across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0

F. Formulary Review - New Drugs- Medical	M. Reisman	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
		Skysona		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Spevigo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Xenpozyme		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Zynteglo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Pedmark		
		Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Elahere		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Imjudo		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
		Tecvayli		
		Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	10:0
G. Formulary Review - Drugs Evaluated Per Grid	M. Reisman	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	10:0
H. Clinical Guidelines	M. Reisman	Clinical Guideline Review		
		Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	10:0
		Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	10:0
		Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	10:0
I. Quality Monitoring	M. Theys/ C. Lichtinger	Confirm Review of Quality Data	Yes/No	Yes
	M. Theys	DUR Review		
	C. Lichtinger	Drug Recalls – 4th Quarter 2022		
	C. Lichtinger	Top 25 Drugs by Spend and Volume – 4th Quarter 2022		
	C. Lichtinger	Top 10 Drugs Requested - Approvals and Denials – 4th Quarter 2022		
	C. Lichtinger	Grievances and Appeals Data – 4th Quarter 2022		
	C. Lichtinger	Inter-Rater Reliability (IRR) – 4th Quarter 2022 • Pharmacists		
Adjournment	G. Shutzberg		6:39 PM EST	

Respectfully Submitted to the Committee,



James P. Hancovsky, M.S.I.A., R.Ph.
Chief Pharmacy Officer, UHC C&S